OBJECTIVES: Primary immunodeficiency disease (PIDD) is a large, heterogeneous group of disorders that weaken the immune system creating a pattern of repeated severe infections. Patients with PID require regular administration of immunoglobulin to prevent infection. This study aims to compare the costs of using SCIG 20% human subcutaneous immunoglobulin 20%, Hizentra®) to intravenous immunoglobulin (IVIG) in the IMSS, in order to identify the cost-saving PIDD treatments. METHODS: Since SCIG 20% and IVIG have the same safety and efficacy profile, a cost-minimization analysis was conducted. The costs in the analysis are the treatment costs for a 72.65 Kg patient in a 5-year time horizon, applying a 5% discount rate on costs. The analysis is presented in 2 scenarios. The first compares SCIG 20% vs IVIG 5% and 6%. The second SCIG 20% vs SCIG 16.5%. All unitary costs are from IMSS in 2016. RESULTS: Monthly dose expected is 43.59 g, so the monthly treatment costs for IVIG 5% and 6% is 2,882.03 USD, meanwhile for SCIG 20% the monthly cost of treatment is 2,713.18 USD. Annual costs for IVIG 5% and 6% is 34,584.32 USD vs